ArticleCase reports in hematology2026
Engraftment Syndrome After Second Autologous Stem Cell Transplantation for Myeloma: A Case Report.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engraftment Syndrome After Second Autologous Stem Cell Transplantation for Myeloma: A Case Report.Case reports in hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engraftment syndrome (ES) is a rare but challenging posttransplant complication, presenting during or after absolute neutrophil recovery. It may easily be confused with febrile infectious complications since its main clinical features include fever, extensive skin rash, diarrhea, and atypical pulmonary infiltrates. Its pathophysiology and potential trigger factors remain not well understood. An immunosuppressive therapy with corticosteroids represents the standard treatment, and most cases present a rapid resolution of symptoms after treatment initiation. Still, in cases of severe presentation including periengraftment respiratory distress syndrome (PERDS), a mortality rate up to 21% has been described. In this case report, we report the case of a male patient after second autologous stem cell transplantation (SCT) with recurrent febrile episodes with no response to usual antibiotic regimens. Our patient developed diarrhea from Day 9 post-SC, escalating to a full-body rash and atypical pneumonia on and after Day 16. Our diagnosis was based on the Maiolino criteria, and a corticosteroid treatment was instituted. The symptoms ceased 2 days later, while we continued the treatment for a week. Physicians should be aware of this rare clinical entity, which can mimic other common posttransplant complications, hindering prompt diagnosis and treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.